Altuviiio Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Altuviiio market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increasing prevalence of rare diseases, the rising incidence of cancer and genetic disorders, the growing adoption of personalized medicine, the expansion of plasma collection centers worldwide, and increased investments in research and development for gene therapy.

The projected growth for the forecast period can be attributed to favorable government initiatives, the rising global prevalence of hemophilia, an increasing demand for effective and affordable treatments, a growing need for advanced therapeutics for genetic disorders, and a higher adoption rate of prophylactic treatments. Key trends during this period include advancements in diagnostic techniques, the development of innovative plasma therapies, progress in gene editing technologies, advancements in biomanufacturing technologies, and ongoing research and development for novel drug therapies.

The growing prevalence of hemophilia is expected to drive the expansion of the altuviiio market in the future. Hemophilia is a rare genetic bleeding disorder that prevents blood from clotting properly due to a deficiency of clotting factors. The increasing number of hemophilia cases is largely due to improved diagnosis and advancements in treatment, which enhance detection and contribute to longer life expectancy. Altuviiio is used to treat hemophilia A by replacing the missing factor VIII, helping to control bleeding episodes with less frequent dosing, thanks to its extended half-life. For instance, as of July 2022, 10,276 individuals with hemophilia were enrolled in treatment centers across 40 countries, with nearly half suffering from severe hemophilia. Most of these patients were male, and many lived in low- to middle-income countries. As the prevalence of hemophilia rises, the altuviiio market continues to grow.

A significant factor driving the altuviiio market is the regulatory approvals that help expand its market presence and enhance access to innovative treatments. Regulatory approvals are official permissions granted by government or authorized agencies to allow the marketing and use of drugs and treatments in specific regions. For example, in February 2023, Sanofi SA received FDA approval for Altuviiio, a groundbreaking once-weekly therapy for hemophilia A. This new factor VIII therapy significantly improves bleeding protection by maintaining near-normal factor activity levels with a single weekly dose. Using innovative Fc fusion technology, Altuviiio offers a longer half-life compared to traditional treatments, leading to fewer bleeding episodes, as clinical trials showed a mean annualized bleeding rate of 0.70. This approval, following multiple designations such as Breakthrough Therapy and Fast Track, represents a major milestone in hemophilia management and offers patients a better quality of life.

In February 2023, Sanofi SA entered into a partnership with Swedish Orphan Biovitrum to develop and commercialize new hemophilia treatments, including Altuviiio, Alprolix, and Elocta/Eloctate. The aim of this collaboration is to enhance patient outcomes and expand global access to life-changing therapies for rare blood disorders. Swedish Orphan Biovitrum, a pharmaceutical company based in Sweden, specializes in treatments for hemophilia.

The key company operating in the altuviiio market is Swedish Orphan Biovitrum.

North America was the largest region in the altuviiio market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in altuviiio report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the altuviiio market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Altuviiio is the brand name for efanesoctocog alfa, an advanced therapeutic product used to treat hemophilia A, a hereditary bleeding disorder caused by a deficiency of clotting factor VIII. It is designed to offer extended protection against bleeding, requiring less frequent dosing than traditional factor VIII therapies, which enhances convenience for patients.

The primary indications for altuviiio are hemophilia A, prophylactic treatment, and on-demand treatment. Hemophilia A is a genetic condition where the blood does not clot properly due to the absence of clotting factor VIII. Altuviiio is distributed through various channels, including hospital pharmacies and specialty pharmacies, and is used by a range of patients, including adults, geriatric patients, and pediatrics.

The altuviiio market research report is one of a series of new reports that provides altuviiio market statistics, including altuviiio industry global market size, regional shares, competitors with an altuviiio market share, detailed altuviiio market segments, market trends and opportunities, and any further data you may need to thrive in the altuviiio industry. This altuviiio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The altuviiio market consists of sales of products including adynovate, advate, kovaltry, and jivi. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.